Connor Clark & Lunn Investment Management Ltd. Has $639,000 Position in ChromaDex Co. (NASDAQ:CDXC)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in ChromaDex Co. (NASDAQ:CDXC) by 10.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,172 shares of the company’s stock after purchasing an additional 17,115 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in ChromaDex were worth $639,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Lazard Asset Management LLC acquired a new position in ChromaDex during the first quarter valued at $43,000. Miracle Mile Advisors LLC acquired a new position in shares of ChromaDex in the 2nd quarter valued at about $27,000. Bank of New York Mellon Corp lifted its position in shares of ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock worth $520,000 after purchasing an additional 119,915 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of ChromaDex in the second quarter worth approximately $124,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of ChromaDex during the second quarter worth approximately $597,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Stock Up 0.7 %

NASDAQ CDXC opened at $7.64 on Friday. The company has a 50 day moving average price of $4.93 and a two-hundred day moving average price of $3.70. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $7.89. The stock has a market capitalization of $583.54 million, a PE ratio of 764.76 and a beta of 1.88.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The firm had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. During the same period in the prior year, the company posted ($0.01) earnings per share. As a group, equities analysts anticipate that ChromaDex Co. will post 0.04 EPS for the current year.

Wall Street Analyst Weigh In

CDXC has been the topic of several research reports. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th. HC Wainwright increased their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, Roth Mkm boosted their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.